Gastroparesis Treatment Market Size to Exceed USD 11.58 Bn by 2032

The Gastroparesis Treatment Market, estimated at USD 8.33 Bn in 2025, is expected to exhibit a CAGR of 4.8% and reach USD 11.58 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Market Dynamics:

Increased prevalence of diabetes: Diabetes remains one of the leading causes of gastroparesis globally. Rising incidence of diabetes, especially type 1 and type 2 diabetes, increases the burden of gastroparesis. As per the International Diabetes Federation, approximately 537 million adults lived with diabetes in 2021 worldwide. This rising diabetes population can boost demand for effective gastroparesis treatments.

Rising geriatric population: The risk of gastroparesis increases with age. Global geriatric population, aged 65 years or older, is growing at an unprecedented rate. As per the United Nations, the number of people aged 65 years or older is projected to increase from 727 million in 2020 to 1.5 billion in 2050. Aging demographic will certainly result in high treatment needs for gastroparesis.

Growing prevalence of diabetes boosts gastroparesis drug development: Growing prevalence of diabetes  can drive the gastroparesis treatment market growth. Diabetes is one of the leading causes of gastroparesis, accounting for over 60% of cases. As per the International Diabetes Federation, approximately 537 million adults lived with diabetes in 2021 globally and this number is estimated to increase to 643 million by 2030 and 783 million by 2045. This increasing diabetes patient pool prompt pharmaceutical companies and researchers to focus on developing novel and effective treatment options for gastroparesis. Several pipeline drugs targeting different disease mechanisms are currently under development and clinical trials, and this is expected to boost the market growth over the forecast period.

Increasing awareness about gastroparesis diagnosis and treatment options

Increasing awareness among patients and physicians about gastroparesis, its diagnosis and available treatment options can drive the market growth. Earlier, gastroparesis was often misdiagnosed or left undiagnosed due to lack of awareness. However, in recent years, various awareness campaigns by support organizations, physicians and social media influence have helped improve understanding of this condition. Thus, more patients are seeking proper diagnosis and treatment rather than ignoring the symptoms. This rising awareness can boost demand for gastroparesis drugs and devices.

High treatment costs limiting widespread adoption

Global gastroparesis treatment market growth can be hampered due to high cost of drug therapies and medical devices. The available drug treatments including prokinetic agents and antiemetic drugs are quite expensive, which makes them unaffordable for many patients, especially in developing countries. Pacemaker-like gastric neurostimulation devices used to treat severe gastroparesis cases involve high upfront device costs along with additional surgical implantation expenses. This steep pricing pressure can hamper the market growth as it limits widespread adoption of therapies across different economic regions.

Complex gastrointestinal anatomy hindering development of novel therapies

The complexity of gastrointestinal anatomy and physiology poses immense challenges towards development of effective and safe gastroparesis therapies. Factors like non-uniform gastric muscle contractions, intricate nerve supply and poor understanding of disease pathophysiology makes it extremely difficult to design novel drug candidates specifically targeting gastroparesis. Failure of several pipeline drug candidates in clinical trials and withdrawal of marketed drugs due to serious side effects points to the complexity of developing gastroparesis treatments. Overcoming these anatomical and biological hurdles requires extensive research investments and prolonged development timelines which can discourage many pharmaceutical companies.

Rising focus on neurostimulation devices after  meta-analysis success

 Gastric neurostimulation devices for treatment of diabetic and idiopathic gastroparesis can offer market growth opportunities. A recent meta-analysis found significant clinical effectiveness of these devices in improving overall symptoms and gastric emptying time. This clinical validation has prompted major industry players to develop next-generation gastrostimulator systems with enhanced features like wireless programming capabilities and rechargeable battery designs. The advantages of non-pharmacological neurostimulation over oral drugs in terms of safety, efficacy and patient compliance makes it an attractive option especially for refractory cases. This increasing confidence in clinical utilities along with ongoing technological refinements can boost demand for neurostimulation devices.

Growing demand for minimally invasive treatment approaches

Developing minimally invasive gastroparesis treatment options favored by both physicians and patients can offer market growth opportunities. There has been rising demand for procedures, devices or techniques allowing treatment without need for complex surgeries, long hospital stays or recovery periods. Examples include endoscopic procedures like gastroscopy and pyloric bulb injections, novel oral drug delivery technologies, non-invasive neurostimulators and implantable pumps. Such minimally invasive approaches offer advantages like rapid symptom relief, reduced complications, shorter treatment durations and better quality of life. Pharmaceutical companies having pipelines focused on these emerging minimally invasive options will have a competitive edge in the future gastroparesis treatment market.

Link - https://www.coherentmarketinsights.com/market-insight/gastroparesis-treatment-market-5123

Key Developments:

• In December 2023, Vanda Pharmaceuticals Inc. announced that the FDA had accepted its New Drug Application (NDA) for tradipitant to treat gastroparesis symptoms. The FDA’s target decision date is September 18, 2024. If approved, tradipitant would be the first new drug for gastroparesis in over 40 years and the first to be reviewed by the FDA in more than 30 years.
• In October 2023, Enterra Medical, Inc. announced that the Enterra II System had received MR Conditional approval from the FDA. This advanced treatment system, including the Enterra 37800 Neurostimulator and Enterra Therapy 4351-35 unipolar leads, is designed to alleviate nausea and vomiting caused by gastroparesis. With MR Conditional status, patients with the Enterra II System can safely undergo MRI scans of the head or limbs under specific conditions.
• In August 2022, Processa Pharmaceuticals, Inc. launched its Phase 2A clinical trial for PCS12852, enrolling the first patient with moderate to severe gastroparesis
• In February 2022, Vanda Pharmaceuticals Inc. (Vanda) announced the results of its Phase III clinical trial, VP-VLY-686-3303, demonstrating the effectiveness and safety of tradipitant in treating symptoms of gastroparesis

Key Players:

Evoke Pharma, Inc., Processa Pharmaceuticals, Inc., Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Otsuka Holdings Co., Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Atlantic Healthcare, Salix Pharmaceuticals, Rhythm Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Medtronic plc, Bausch Health Companies Inc., Sanofi S.A.